Lexicon Pharmaceuticals (LXRX) Projected to Post Quarterly Earnings on Tuesday

Lexicon Pharmaceuticals (NASDAQ:LXRX) is expected to announce its Q3 2025 results before the market opens on Tuesday, November 11th. Analysts expect the company to announce earnings of ($0.07) per share and revenue of $5.8110 million for the quarter. Parties may visit the the company’s upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Thursday, November 6, 2025 at 8:30 AM ET.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last issued its quarterly earnings results on Wednesday, August 6th. The biopharmaceutical company reported $0.01 earnings per share for the quarter, beating the consensus estimate of ($0.08) by $0.09. Lexicon Pharmaceuticals had a negative return on equity of 83.63% and a negative net margin of 206.43%.The firm had revenue of $28.87 million during the quarter, compared to the consensus estimate of $4.87 million. On average, analysts expect Lexicon Pharmaceuticals to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Lexicon Pharmaceuticals Stock Up 0.4%

Shares of NASDAQ:LXRX traded up $0.01 on Tuesday, hitting $1.37. 244,767 shares of the company traded hands, compared to its average volume of 7,027,062. Lexicon Pharmaceuticals has a 52 week low of $0.28 and a 52 week high of $1.66. The company has a quick ratio of 4.16, a current ratio of 4.16 and a debt-to-equity ratio of 0.43. The stock has a 50 day simple moving average of $1.30 and a 200-day simple moving average of $1.02. The company has a market cap of $496.04 million, a PE ratio of -4.17 and a beta of 1.23.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Hudson Bay Capital Management LP bought a new position in Lexicon Pharmaceuticals in the 2nd quarter worth approximately $26,000. XTX Topco Ltd raised its holdings in Lexicon Pharmaceuticals by 431.4% during the 2nd quarter. XTX Topco Ltd now owns 66,276 shares of the biopharmaceutical company’s stock valued at $63,000 after buying an additional 53,805 shares during the period. Bank of America Corp DE increased its stake in Lexicon Pharmaceuticals by 27.4% in the fourth quarter. Bank of America Corp DE now owns 136,407 shares of the biopharmaceutical company’s stock worth $101,000 after purchasing an additional 29,319 shares during the period. Invesco Ltd. increased its stake in Lexicon Pharmaceuticals by 173.5% in the first quarter. Invesco Ltd. now owns 285,759 shares of the biopharmaceutical company’s stock worth $132,000 after purchasing an additional 181,265 shares during the period. Finally, Cerity Partners LLC increased its stake in Lexicon Pharmaceuticals by 21.1% in the second quarter. Cerity Partners LLC now owns 206,279 shares of the biopharmaceutical company’s stock worth $195,000 after purchasing an additional 35,892 shares during the period. 74.70% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

LXRX has been the subject of several analyst reports. Wall Street Zen upgraded Lexicon Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday, October 4th. Weiss Ratings reissued a “sell (d-)” rating on shares of Lexicon Pharmaceuticals in a research report on Wednesday, October 8th. Citigroup boosted their target price on Lexicon Pharmaceuticals from $1.20 to $1.90 and gave the stock a “buy” rating in a research report on Thursday, August 7th. Finally, HC Wainwright reissued a “buy” rating and issued a $4.00 target price on shares of Lexicon Pharmaceuticals in a research report on Tuesday, September 2nd. Three research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $3.23.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.